AbbVie (ABBV) has submitted an application to the US FDA seeking approval for SKYRIZI for subcutaneous (SC) induction for the treatment of adult patients with moderately to severely active Crohn's disease

AbbVie's application to the US FDA for SKYRIZI signals a strategic move to expand its treatment portfolio, particularly for Crohn's disease. The backing from the Phase 3 AFFIRM study adds weight to the application, suggesting that if approved, it could bolster AbbVie's market position and revenue growth in the gastrointestinal treatment space. Investors should monitor potential implications for sales forecasts and the competitive landscape in the biotechnology sector.